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 Abstract 
 Background: Recent neuroimaging studies in humans support the clinical observations that 
the motor cortex is affected early in the course of Alzheimer’s disease (AD).  Patients and Meth-
ods: We measured the silent period (SP) induced by transcranial magnetic stimulation in AD 
patients in the very early stage of the disease, and we explored whether and in which way the 
pharmacologic manipulation of the cholinergic system could modify it.  Results: An increase in 
the duration of the SP was observed in AD patients in the early stage in comparison to controls. 
After 2 months of treatment with donepezil, the duration did not differ significantly from that 
of normal subjects. The results of our study show a fragmentation and an enlargement of the 
SP in the presence of multiple late excitatory potentials (LEPs) in early untreated AD patients. 
These LEPs were also modulated by donepezil.  Conclusions: The results suggest an early func-
tional impairment of cholinergic neurotransmission in AD. The disturbance in acetylcholine 
output in early AD leads to a decrease in excitability of the motor system. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD) is a neurodegenerative disorder which does not spare the 
motor cortex. Experimental paradigms  [1] and clinical studies  [2–4] confirm the clinical 
observations about early involvement of motor behavior in AD patients. The main neurotrans-
mitters implicated in the regulation of the motor cortex are acetylcholine (ACH) and glutamate 
as basically excitatory  [5, 6] and GABA as the basic inhibitory neurotransmitter  [7] . The 
cholinergic hypothesis about the central role of ACH in cognitive deterioration in AD in the 
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light of new evidence in vitro  [8, 9] and in vivo  [10, 11] is enriched so as to suggest ACH as the 
main neurotransmitter regulating not only the cognitive but also the motor functions in AD 
patients already from the early stage.
 Transcranial magnetic stimulation (TMS) has been widely used to assess the excitatory 
and inhibitory mechanisms which regulate the function of the motor cortex in AD  [1, 12–14] . 
The effect of the cholinergic system on these inhibitory mechanisms has been extensively 
explored by TMS  [15, 16] . A strong decrease in short-latency afferent inhibition which was 
reversed by acetylcholinesterase inhibitor intake was observed in various studies with AD 
patients  [17] . A dominant role of ACH and a probable role of GABA as the intermediate 
neurotransmitter in motor control have been assumed, but a clear hypothesis concerning the 
underlying neuronal circuits has not yet been formed. 
 Among the neurophysiological parameters more often used in TMS, the silent period (SP) 
is considered as a direct indicator for cortical inhibition. It provides information about the 
underlying pathophysiological mechanisms, especially when measured in subjects taking 
pharmacological agents with an effect upon basic neurotransmitters  [9, 16, 18] . The SP is 
defined as the interval of the cease of electromyographic activity which follows the production 
of a motor-evoked potential (MEP) in a muscle sustaining isometric voluntary contraction 
after the application of TMS in the primary motor area (M1). SP duration is the main parameter 
used to assess the cortical inhibition and is defined as the difference between the SP onset 
and the SP offset. However, the methods used to determine the onset and offset of the SP differ 
widely between studies. The SP onset has been defined as the onset of TMS, the MEP onset, 
the MEP offset, or when electromyography (EMG) drops below the volitional pre-TMS EMG 
level. The SP offset has been defined as the first return of any volitional EMG, the absolute 
return of EMG to the pre-TMS level, or when EMG no longer significantly differs from the 
pre-TMS EMG level  [19, 20] . The evaluation of the whole SP duration is also difficult as some-
times, it can be temporarily interrupted by an electromyographic breakthrough of short 
duration and a low amplitude called ‘late excitatory potential’ (LEP), leading to a false, shorter 
SP. Several LEPs can scatter the SP into a lot of valleys until the final return of the full electro-
myographic activity. The occurrence of LEPs could be due to the activation of slow motor 
pathways or due to the activation of reflex pathways, but the most prominent hypothesis 
links them to cortical disinhibition  [21] .
 Up until now, the SP has not been extensively studied in AD patients. The main reasons 
for this are the general problems arising with the calculation of the SP such as the consid-
erable interindividual variation of its duration, the high degree of intraindividual asymmetry, 
the variable results when different examiners apply the TMS in the same subject  [22] , and the 
difficulty of an AD patient to collaborate. 
 In the present study, single-pulse TMS was applied in early AD patients before and after 
donepezil intake; the parameters of the SP were measured in order to explore the underlying 
cortical circuits.
 Patients and Methods 
 Patients 
 Thirteen right-handed patients with AD (6 men, 7 women, mean age 72.9 ± 8.4 years) 
were studied. All patients were diagnosed with probable AD according to the criteria of the 
National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer 
Disease and Related Disorders Association. They were in an early stage of the disease 
according to the Clinical Dementia Rating Scale. The Mini Mental State Examination (MMSE) 
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signs of other neurological diseases or those who were on medications with a possible effect 
on the cognitive function or the excitability of the nervous system were excluded. The neuro-
logical motor examination was normal. The patients were independent in the elementary 
activities of daily living even if some instrumental activities of daily living were impaired. All 
the patients underwent a brain MRI to exclude cerebral vascular lesions or any cause of 
reversible dementia.
 All AD patients had the examination performed before the introduction of treatment with 
a cholinesterase inhibitor (10 mg donepezil per week once a day). The whole procedure was 
repeated after 2 months of treatment in all patients except one (patient 11) who did not 
reappear for the follow-up.
 The age-matched (71.5 ± 8.4 years) control group consisted of 13 right-handed normal 
subjects (7 men, 6 women) with no history of neurological disease and a completely normal 
neurological examination. 
 All patients and all normal subjects were able to collaborate well during the electrophys-
iological procedure. They gave informed consent for the study which was approved by the 
local ethics committee.
 Methods 
 The patients and normal subjects were seated comfortably on a chair in a quiet exami-
nation room. The EMG of the right abductor digiti minimi was recorded in a Nicolet Viking IV 
IES 405-1 EMG machine to assess the response to TMS.
 TMS was used in accordance with the consensus guidelines  [23] . It was applied by a 
Magstim 200 stimulator (Magstim Ltd., Whitland, UK) through a 9-cm diameter circular coil, 
located at the vertex area of the scalp. The center of the coil was measured on the line between 
the nasion and the union point for each patient to ensure the reproducibility of the procedure 
from the first session to the second one 2 months later. The circulating current was turning 
clockwise in order to elicit a response in the target muscle. The subjects were asked to 
perform a slight isometric voluntary contraction of the right abductor digiti minimi (around 
10% of the maximum voluntary muscle contraction) during TMS, with an auditory feedback. 
This active cortical motor threshold, defined as the minimal intensity of cortical stimulation 
which produces MEPs of approximately 200 μV in 50% of consecutive trials during isometric 
contraction of the tested muscle, at about 20% of maximum voluntary contraction, was 
determined by lowering the stimulator output gradually from 60% of the maximal output. 
Once the active motor threshold (aMT) was determined, the intensity of the output of the 
magnetic stimulator was pushed to 150% of the threshold. The patients were asked to 
perform a voluntary contraction of the target muscle of about 50% of the maximal voluntary 
contraction assessed by amplitude of the EMG response. The base time of the recordings was 
500 ms.
 We have chosen to measure the SP ‘valley’ defining the onset of the SP by the MEP offset 
and the offset of the SP by the return of the electromyographic activity in an amplitude which 
no longer differed from the pre-EMG level and not by the first return of any volitional EMG. 
 The duration of the SP was analyzed as well as the presence or absence of LEPs and, when 
present, their latency, amplitude and duration.  The results were compared and statistically 
analyzed between groups by using unpaired Student’s t test.
 Results 
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if LEP is 
present, ms
SP duration 
if LEP is 
absent, ms
Normal subjects
1 no 125 125
2 no 132 132
3 no 58 58
4 no 122 122
5 no 187 187
6 no 89 89
7 yes 229 111 487 67 229
8 no 47 47
9 no 71 71
10 no 145 145
11 no 136 136
12 no 116 116
13 no 62 62
Mean 116.8 111 487 67 229 107.5
SD 52.6 42.2
AD patients before treatment
1 yes 262 18 1,100 46 262
2 no 45 45
3 yes 182 27 798 112 182
4 no 86 86
5 yes 162 32 812 98 162
6 yes 176 42 625 61 176
7 yes 364 55 563 181 364
8 yes 173 86 650 62 173
9 no 95 95
10 yes 238 74 1,800 94 238
11 yes 223 68 625 102 223
12 yes 285 49 368 134 285
13 no 132 132
Mean 186.4 50.1 815.7 98.9 229.4 89.5
SD 88.2 22.8 420.5 41.5 66.3 35.7
AD patients after treatment
1 yes 274 52 662 137 274
2 no 112 112
3 yes 139 23 854 73 139
4 no 140 140
5 yes 261 36 614 102 261
6 no 54 54
7 yes 214 41 1,120 64 214
8 no 68 68
9 yes 284 81 1,052 108 284
10 no 94 94
12 no 86 86
13 no 80 80
Mean 150.5 46.6 860.4 96.8 221.2 90.6
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 Normal Subjects 
 The mean ± SD aMT for normal subjects was 32.8 ± 7.7%. EMG following TMS generally 
showed the pattern of an MEP at a latency of around 20 ms followed by an SP of variable duration. 
LEPs were observed in 1/13 subjects (7%;  patient L., 70 years old) with a latency of 67 ms, an 
amplitude of 487 μV and a duration of 111 ms. The SP duration for this subject was 229 ms.  For 
the other normal subjects, the mean duration of the SP was 107.5 ± 42.2 ms. When the subject 
L. was included, the duration of the SP was 116.8 ± 52.6 ms.
 AD before Treatment 
 Before treatment with donepezil, the mean aMT in the 13 AD patients was 37.6 ± 3.9%. 
In these patients, the mean duration of the SP was 186.4 ± 88.2 ms. It was significantly 
increased by comparison to normal subjects (p < 0.001).
 In 9 out of 13 patients, LEPs were evident (69%), with a mean latency of 98.9 ± 41.5 ms, 
a mean amplitude of 815.7 ± 420.5 μV and a mean duration of 50.1 ± 22.8 ms.  The SP valley 
was fragmented in these patients into multiple segments before the true return of full EMG 
activity ( fig. 1 ). In the 9 patients with an LEP, the mean duration of the SP was 229.4 ± 66.3 
ms, which differed significantly from the normal subjects (p < 0.001). In the 4 patients without 
an LEP, the mean duration of the SP was 89.5 ± 35.7 ms (not statistically significant compared 
to normal subjects).
 AD after Treatment 
 Two months after treatment with donepezil, the mean aMT in the 12 AD patients was 
33.5 ± 3.5%. The mean duration of the SP was 150.5 ± 85.0 ms. There was no significant statis-
tical difference with the normal subjects or AD patients before treatment.
 LEPs occurred in 5 out of 12 patients (42%), with a mean latency of 96.8 ± 29.2 ms, a 




 Fig. 1. Examples of LEPs in a nor-
mal subject and 2 untreated AD 
patients (base time: 50 ms/divi-
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significant difference in latency, amplitude or duration of the LEPs between the patients 
before and after the treatment.  In the 5 patients with an LEP, the mean duration of the SP was 
221.2 ± 87.1 ms, which was not significantly different from the duration of SP in AD patients 
with an LEP before treatment. In the 7 patients without an LEP, the mean duration of the SP 
was 90.6 ± 28.6 ms, which was also not significant compared to the 4 patients without an LEP 
before treatment and to the normal subjects.
 Discussion 
 In our study, the duration of the whole SP valley was significantly increased in untreated 
AD patients compared to normal subjects. After treatment with donepezil, the duration of the 
SP valley decreased. A significant increase in LEP occurrence causing a fragmentation of the SP 
valley was also observed in AD patients compared to normal subjects, with a trend to normalize 
when patients were treated with donepezil. The duration, the amplitude and the latency of 
LEPs in AD patients did not show any significant difference before and after treatment.
 Combining those results, we could hypothesize that the increased duration of the whole 
SP valley in AD patients before treatment could be due to the presence of multiple LEPs. The 
presence of an LEP itself is indicative of cortical disinhibition  [21] . The observed return of an 
SP valley to normal values along with the decrease in LEP occurrence after donepezil intake 
suggest a cholinergic control of the neuronal circuits controlling the genesis of the LEP and 
the duration and shape of the SP in early AD patients.
 Based on Orth and Rothwell  [24] , and later supported by more studies  [19, 20] , there is 
a strong correlation between the production of MEP and SP occurrence. It is already known 
that TMS primarily activates the fast-conducting pyramidal neurons leading to the genesis of 
MEP. However, from experiments in cats  [25] it is also known that recurrent collaterals of 
these fast-conducting neurons have an inhibitory effect on slower-conducting pyramidal 
neurons most probably by exciting intercalated inhibitory neurons. As slow-conducting pyra-
midal neurons are responsible for the maintenance of tonic voluntary muscle contraction, the 
inhibition of those neurons is presumed to be responsible for SP occurrence.
 Neuroanatomy and animal experiments indicate that in the layer I of M1 there is a very 
rich presence of cholinergic fibers which lessens in layers II–III  [25, 26] . In layers II–III, the 
apical dendrites of pyramidal cells (PC) are found, which have cholinergic afferents. A strong 
release of ACH from cholinergic axons located in layer I can therefore stimulate the PC by 
acting on their muscarinic receptors. In addition, the layers II–III of the motor cortex are very 
rich in GABAergic neurons  [27, 28] . The basket which GABAergic neurons specifically form 
by their axons is a connecting network with the apical dendrites of PC located there.
 The results of our study show a fragmentation and an enlargement of the SP in the 
presence of multiple LEPs in early untreated AD patients. Along with the neurophysiological 
model of Orth and Rothwell  [24] we suggest that the disturbance in ACH output in early AD 
leads to a decrease in excitability of the PC. Subsequently, the excitability of the intercalated 
inhibitory GABAergic neurons is reduced. Less inhibition is exerted by the GABAergic neurons 
onto the slow-conducting PC responsible for the maintenance of the voluntary isometric 
contraction. As a final outcome, various LEPs appear which fragment the SP valley and 
increase its duration.
 Donepezil intake tends to normalize the shape and duration of the SP with less LEP occur-
rence, which strongly supports the aforementioned hypothesis. The observation that in 
normal subjects LEPs are extremely rare is also in favor of our hypothesis of the central role 
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 While LEP occurrence appears to be strongly influenced by the cholinergic system, the 
mean latency, duration and amplitude of LEPs does not differ in all 3 groups, suggesting a 
noncholinergic mechanism which determines those parameters. Moreover, ACH cannot 
completely inhibit LEP occurrence in all AD patients. In the cases where LEPs persist despite 
treatment, the SP has a similar duration to that of the untreated AD patients. Maybe this could 
be due to a lack of therapeutic efficacy of donepezil. However, the correlation between the 
clinical responsiveness to donepezil and LEP occurrence was not studied here. Also, the 
significance of the LEP occurrence in one normal subject is not clear. Further studies are 
needed to examine the utility of LEPs as potential biomarkers.
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